Evidence map›Paper›PMID 36897502›Full record

ArticleInternational journal of hematology2023

Unrelated hematopoietic stem cell transplantation for familial platelet disorder/acute myeloid leukemia with germline RUNX1 mutations.

Kazunori Toratani, Mizuki Watanabe, Junya Kanda, Tomomi Oka, Mizuki Hyuga, Yasuyuki Arai, Makoto Iwasaki, Maki Sakurada, Yasuhito Nannya, Seishi Ogawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Targeting RUNX1 Germline Variants: Agents Under Investigation.Current hematologic malignancy reports · 2025
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kazunori TorataniDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Mizuki WatanabeDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan. jkanda16@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-6704-3633
Tomomi OkaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Mizuki HyugaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Yasuyuki AraiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Makoto IwasakiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Maki SakuradaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Takahiro YamadaClinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Kyoto, Kyoto, 606-8507, Japan.
Kyoto University · JPKyoto University Hospital · JP

Funding

Japan Agency for Medical Research and Development JP19ck0106250h0003Japan Agency for Medical Research and Development JP19ck0106353h0003Japan Agency for Medical Research and Development JP19cm0106501h0004Japan Society for the Promotion of Science JP15H05909Japan Society for the Promotion of Science JP18H02836Japan Society for the Promotion of Science JP19H05656Japan Society for the Promotion of Science JP26221308
6 · The paper itself

Abstract

Germline mutations in RUNX1 result in rare autosomal-dominant familial platelet disorder with predisposition to acute myeloid leukemia (FPD/AML). As genetic analysis is becoming increasingly prevalent, the diagnosis rate of FPD/AML is expected to increase. In this report, we present two pedigrees, one diagnosed molecularly and another highly suspected to be FPD/AML, whose members both received allogeneic hematopoietic stem cell transplantation (HSCT). Both pedigrees had a family history of thrombocytopenia, platelet dysfunction, and hematological malignancies. One family inherited a frameshift mutation (p.P240fs) of RUNX1, a known pathogenic variant. Another family inherited a point mutation (p.G168R) in the runt-homology domain, the clinical significance of which is uncertain at this point. As this mutation was completely absent from all population databases and had a relatively high REVEL score of 0.947, we thought that it would be dangerous to ignore its possible pathogenicity. Consequently, we avoided choosing HSCT donors from relatives of both families and performed HSCT from unrelated donors. In conclusion, our experience with two families of FPD/AML highlights the importance of searching for gene mutations associated with germline predisposition and indicates the necessity of developing a donor coordination system for FPD/AML patients, as well as a support system for families.

Indexed as

Blood Platelet DisordersHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteCore Binding Factor Alpha 2 SubunitGerm CellsGerm-Line MutationHumansMutationCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanAcute myeloid leukemiaFamilial platelet disorderGenetic pedigreeGermlineMyelodysplastic syndromeRUNX1 mutation

Identifiers

PMID36897502
OpenAlexW4323812342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.